

RAPID ANTIBODY DISCOVERY SERVICES

Invenra's Rapid Discovery Services provide an efficient, industry-leading approach to discovering monoclonal and bispecific antibodies. With cutting-edge phage display technology and our streamlined workflow, we deliver high-quality antibody leads in record time.

RAPID BISPECIFIC DISCOVERY


FEATURES:

- **Inputs:** Target ID(s), recombinant proteins, and cell lines
- **Deliverables:** 10 unique B-Body® Bispecific Antibody sequences
- **Timeline – 4 months** from sequence submission to delivery

PROCESS


- 1 **Assessment** – Invenra assesses target feasibility and compatibility for the Rapid Discovery Workflow
- 2 **Handoff** – Clients supply purified recombinant antigens and necessary cell lines, or Invenra can source materials at an additional fee
- 3 **Library Screening** – Invenra screens >30 proprietary human phage libraries under three selection conditions, conducting **90 screens** in parallel
- 4 **Binding Validation** – Cross-reactivity testing with up to three additional species/related proteins and affinity (KD) measurements
- 5 **Bispecific Expression** – A 12x12 B-Body Bispecific matrix in two orientations (a total of **288 total combinations**) is expressed, purified, and screened
- 6 **Selection and Assay** – Top candidates are confirmed for target binding, self-association, polyreactivity, and functionality using a high-throughput screening assay
- 7 **Delivery** – Data is shared with the client, and **the top 10 B-Body Bispecific sequences are delivered**

IVENRA RAPID B-BODY® BISPECIFIC DISCOVERY: 4 MONTHS TO NOVEL BISPECIFIC ANTIBODY LEADS



ADVANTAGES:

- **Speed** – Fastest timelines in the industry for bispecific discovery
- **Proprietary Libraries** – Gain access to Invenra's proprietary antibody libraries, and the best possible lead molecules
- **Seamless B-Body integration** – Build your bispecifics on the premiere bispecific platform with CMC-ready, in-platform discovery and proven performance
- **Flexible Commercial Licensing Options** – Please contact us to discuss pricing and terms



RAPID MONOCLONAL DISCOVERY

FEATURES:

- **Inputs:** Target ID(s), recombinant proteins, and cell lines
- **Deliverables:** 15 monoclonal antibody sequences
- **Timeline** – 2 months from sequence submission to delivery

PROCESS


- 1 **Assessment** – Invenra assesses target feasibility and compatibility for the Rapid Discovery Workflow
- 2 **Handoff** – Clients supply purified recombinant antigens and necessary cell lines.
- 3 **Library Screening** – Invenra screens >30 proprietary human phage libraries under three selection conditions, conducting 90 screens in parallel
- 4 **Binding Validation** – Cross-reactivity testing with up to three additional species/related proteins and affinity (KD) measurements
- 5 **Selection and Assay** – Developability assessments ensure the highest-quality mAb candidates
- 6 **Delivery** – Data is shared with the client, and the top 15 monoclonal sequences are delivered

ADVANTAGES:

- **Speed** – Fastest timelines in the industry for monoclonal discovery.
- **Proprietary Libraries** – Gain access to Invenra's proprietary antibody libraries, and the best possible lead molecules
- **Flexible Commercial Licensing Options** – Please contact us to discuss pricing and terms

INVENRA RAPID mAb DISCOVERY: 2 MONTHS TO NOVEL MONOCLONAL LEADS

PARTNER PROVIDED ANTIGENS



NOVEL LEAD mAbs IN 2 MONTHS